Back to Search Start Over

Virtual reality or isokinetic training; its effect on pain, kinesiophobia and serum stress hormones in chronic low back pain: A randomized controlled trial.

Authors :
Nambi G
Abdelbasset WK
Alrawaili SM
Alsubaie SF
Abodonya AM
Saleh AK
Source :
Technology and health care : official journal of the European Society for Engineering and Medicine [Technol Health Care] 2021; Vol. 29 (1), pp. 155-166.
Publication Year :
2021

Abstract

Background: Evidence on the latest technologies in rehabilitation for reducing pain and altering serum stress hormones in low back pain (LBP) was lacking.<br />Objective: To find the clinical and hormonal effects of virtual reality training (VRT) and isokinetic training (IKT) in chronic LBP patients.<br />Methods: Through the simple random sampling method, 60 university football players with chronic LBP were allocated into three groups: NVRT= 20, NIKT= 20 and NCONTROL= 20. The three groups underwent different exercises for 4 weeks. Clinical (pain intensity and kinesiophobia) and hormonal (glucose, insulin, HOMA-IR, growth hormone, prolactin, ACTH and cortisol) values were measured at baseline, after 4 weeks and 6 months.<br />Results: Four weeks following training, the VRT and IKT groups showed significant changes in pain intensity and kinesiophobia in comparison to the control group (p< 0.05). Hormonal measures also showed significant improvement in the VRT group in comparison to the other two groups (p< 0.05).<br />Conclusion: Training through virtual reality and isokinetic exercise is an effective approach in terms of pain and kinesiophobia. In terms of hormonal analysis, virtual reality shows slightly more improvements than isokinetic training in subjects with chronic LBP.

Details

Language :
English
ISSN :
1878-7401
Volume :
29
Issue :
1
Database :
MEDLINE
Journal :
Technology and health care : official journal of the European Society for Engineering and Medicine
Publication Type :
Academic Journal
Accession number :
32831210
Full Text :
https://doi.org/10.3233/THC-202301